Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.74 |
| ▸ | BRAF | P15056 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939560 | 0.88 | BRAF (0.74) | CSF1RBRAF | |
| SCHEMBL3943702 | 0.87 | CSF1R (0.70) | CSF1RBRAFCYP11B2 | |
| SCHEMBL3932168 | 0.86 | CSF1R (0.60) | CSF1RBRAF | |
| SCHEMBL1276793 | 0.85 | CSF1R (1.00) | CSF1RBRAF | |
| SCHEMBL3930169 | 0.84 | CSF1R (0.62) | CSF1RBRAF | |
| SCHEMBL3937374 | 0.83 | CSF1R (0.80) | CSF1RBRAFNPC1RAB9ACYP11B2 | |
| SCHEMBL3941840 | 0.83 | CSF1R (1.00) | CSF1RBRAFNPC1 | |
| SCHEMBL3934183 | 0.83 | CSF1R (1.00) | CSF1RBRAFNPC1RAB9A | |
| SCHEMBL3930070 | 0.83 | CSF1R (1.00) | CSF1RBRAFNPC1RAB9A | |
| SCHEMBL3936075 | 0.82 | CSF1R (1.00) | CSF1RBRAFNPC1RAB9ACYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | claimed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | US | disclosed |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | disclosed |
| US-8507656-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20110044998-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| CN-101128454-A | Pyridine carboxamide derivatives for use as anticancer agents | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | TEK, VEGFA, THPO | CSF1R 118/4885BRAF 2937/4885NPC1 4122/4885 |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | TEK, VEGFA, THPO | CSF1R 118/4885BRAF 2937/4885NPC1 4122/4885 |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | TEK, VEGFA, THPO | CSF1R 118/4885BRAF 2937/4885NPC1 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.